FASEB SRC: The Consequences of Aneuploidy: Honoring the Contributions of Angelika Amon

FASEB SRC：非整倍体的后果：纪念 Angelika Amon 的贡献

• 批准号: 10467260
• 负责人: Jason Sheltzer
• 金额: $ 3.5万
• 依托单位: FEDERATION OF AMER SOC FOR EXPER BIOLOGY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-13 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10467260
• 关键词: Address; American; Aneuploid Cells; Aneuploidy; Area; Automobile Driving; Biology; Cells; Child; Chromosomal Instability; Chromosome Segregation; Chromosomes; Clinical; Complement; DNA Sequence Alteration; Development; Disease; Down Syndrome; Drug resistance; Event; Exhibits; Extinction (Psychology); Friends; Funding; Genes; Genetic; Goals; Grant; Growth; Haploidy; Health; Human; Husband; Individual; Intellectual functioning disability; International; Logistics; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of ovary; Massachusetts; Memory; Organism; Patient-Focused Outcomes; Physiology; Research; Research Personnel; Science; Scientist; Secure; Series; Societies; Stress; United States; Widowhood; base; career; career development; chromosome missegregation; cost; dosage; experience; member; outreach; posters; professor; symposium; tumor

Abstract We are requesting grant support for a new FASEB conference entitled “The Consequences of Aneuploidy: Honoring the Contributions of Angelika Amon.” This conference will be held from September 11th to 16th, 2022, in Southbridge, Massachusetts. The broad goals for this conference are two-fold: first, to bring together the world’s leading experts in studying the consequences of aneuploidy, and second, to honor the contributions of Angelika Amon, a pioneer of aneuploidy research who passed away from ovarian cancer in 2020. Aneuploidy, or a chromosome copy number state that is not a whole-number multiple of an organism’s normal haploid complement, is a hallmark of malignant growth and is the most common genetic cause of intellectual disability. Current sequencing-based estimates suggest that up to 90% of human tumors exhibit aneuploidy, and high levels of aneuploidy are associated with metastatic disease, drug resistance, and dismal patient outcomes. Despite the ubiquity of aneuploidy in cancer and its significance to human health, there are no regular conferences in the United States dedicated to sharing the latest advances on this class of genomic alterations. We aim to establish a new conference on this topic that will serve as a forum to bring together scientists to share the latest advances in this exciting and fast-moving field. The organizing team for this conference consists of leading aneuploidy researchers who were Angelika’s colleagues and trainees and are convening this inaugural conference in her memory. This team has already secured the support of FASEB for this conference, which will provide significant organizational, logistic, and technical support for the event. R13 grant funding is being requested to subsidize the costs for early-career researchers and researchers from under-represented backgrounds to attend this event. We currently have 41 confirmed speakers across 10 topic areas related to aneuploidy and chromosome segregation, with a particular focus on the impact of aneuploidy on tumor development and human health. Additional programming is planned for early-career scientists, including a series of short talks, two poster sessions, and several career-development events.

抽象的 我们正在请求为题为“非整倍体的后果： 表彰 Angelika Amon 的贡献。”本次会议将于 2022 年 9 月 11 日至 16 日举行， 这次会议的主要目标有两个：首先，汇聚各方力量。 世界领先的专家在研究非整倍性的后果，其次，以表彰他们的贡献 安吉莉卡·阿蒙 (Angelika Amon)，非整倍体研究先驱，于 2020 年因卵巢癌去世。 非整倍体，或染色体拷贝数状态不是生物体正常拷贝数的整数倍 单倍体补体，是恶性生长的标志，也是智力障碍最常见的遗传原因 目前基于测序的估计表明，高达 90% 的人类肿瘤表现出非整倍性，并且 高水平的非整倍性与转移性疾病、耐药性和糟糕的患者预后有关。 尽管非整倍体在癌症中普遍存在并且对人类健康具有重要意义，但目前还没有常规的方法 在美国举行的会议致力于分享此类基因组改变的最新进展。 我们的目标是就这个主题建立一个新的会议，作为一个论坛，让科学家们聚集在一起分享 这个令人兴奋且快速发展的领域的最新进展本次会议的组织团队由以下人员组成。 领先的非整倍体研究人员是 Angelika 的同事和实习生，他们正在召开这次首届会议 她的记忆中的会议已经获得了 FASEB 对这次会议的支持。 正在为该活动提供重要的组织、后勤和技术支持。 要求补贴早期职业研究人员和代表性不足的研究人员的费用 目前，我们已确认 41 位演讲者，涉及 10 个主题领域。 非整倍性和染色体分离，特别关注非整倍性对肿瘤的影响 计划为职业生涯早期的科学家提供额外的节目，包括一系列节目。 简短的演讲、两次海报会议和几次职业发展活动。